DUBLIN--(BUSINESS WIRE)--The "Axial Spondyloarthritis: Forecast in Asia-Pacific Markets to 2028" report has been added to ResearchAndMarkets.com's offering.

Summary:

Axial Spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Axial Spondyloarthritis (AxSpA) usually starts in the third decade of the life, and can have a major impact on patient health-related quality of life and work productivity.

Axial Spondyloarthritis (AxSpA) is an insidious disease and difficult to diagnose. Diagnosis is aided by family history, clinical examination, C-reactive protein (CRP), HLA-B27 testing and radiographic imaging. Diagnoses of Axial Spondyloarthritis (AxSpA) patients have an average delay of eight years from the onset of symptoms.

Of the 5GM (Australia, China [urban], India, South Korea and Japan), China (urban) is expected to have the highest number of diagnosed prevalent cases, increasing from 3.1 million cases in 2018 to 4.1 million cases in 2028. There were 2.8 million cases in India while Australia had 0.08 million diagnosed prevalent cases in 2018. The major drivers for the upward trend in the diagnosed prevalent cases of Axial Spondyloarthritis (AxSpA) in the 5GM (Australia, China [urban], India, South Korea and Japan) over the next decade is partly attributable to aging population combined with the increasing trend in the prevalence of the condition.

The latest report, Axial Spondyloarthritis: Epidemiology Forecast in Asia-Pacific Markets to 2028, provides an overview of the risk factors and historical trends for Axial Spondyloarthritis across the 5GM (Australia, China [urban], India, South Korea and Japan) in the ages 18 years.

Scope:

• Overview of axSpA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Annualized axSpA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the axSpA therapeutics market.
• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the Asia-Pacific axSpA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Axial Spondyloarthritis: Executive Summary

2.1 Axial Spondyloarthritis Market to Experience Mild Growth from 2018-2028

2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves

2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period

2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Axial Spondyloarthritis Pipeline

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario

5.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Base Scenario

5.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario

5.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA - Alternative Scenario

5.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients

5.5 Epidemiological Forecast for AS and Nr-axSpA (2018-2028) - Base Scenario

5.5.1 Diagnosed Prevalent Cases of AS

5.5.2 Diagnosed Prevalent Cases of Nr-axSpA

5.6 Epidemiological Forecast for AS and Nr-axSpA (2018-2028) - Alternative Scenario

5.6.1 Diagnosed Prevalent Cases of AS

5.6.2 Age-Specific Diagnosed Prevalent Cases of AS

5.6.3 Sex-Specific Diagnosed Prevalent Cases of AS

5.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity

5.6.5 Diagnosed Prevalent Cases of Nr-axSpA

5.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-axSpA

5.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-axSpA

5.7 Discussion

5.7.1 Epidemiological Forecast Insight

5.7.2 Limitations of the Analysis

5.7.3 Strengths of the Analysis

6 Disease Management in APAC

6.1 Diagnosis and Treatment Overview

6.2 India

6.3 China

6.4 Australia

6.5 South Korea

6.6 Japan

7 Competitive Assessment

8 Unmet Needs and Opportunity Assessment in APAC

9 Current and Future Players in APAC

10 APAC Markets

11 Appendix

Companies Mentioned

• AbbVie
• Novartis
• UCB
• Janssen
• Eli Lilly
• Pfizer
• Kyowa Hakko Kirin

For more information about this report visit https://www.researchandmarkets.com/r/hl24e

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900